AMCC Applied Micro Circuits Corp.

---

---

---

---

*

The amounts reclassified from accumulated other comprehensive loss and recorded in net realized gain on short-term investments and interest income, net in the Condensed Consolidated Statement of Operations relating to sale of short-term investments were zero and $1.5 million for the three and nine months ended December 31, 2015, respectively, and $0.1 million each for the three and nine months ended December 31, 2014. Refer to Note 2, Certain Financial Statement Information, to the Condensed Consolidated Financial Statements for additional details.

---

---

•	capitalized mask sets including their useful lives, which affect cost of goods sold and property and equipment or R&D expenses, if not capitalized;

•	inventory valuation, warranty liabilities and revenue reserves, which affect cost of sales, gross margin, and revenues;

•	allowance for doubtful accounts, which affects operating expenses;

•	unrealized losses or other-than-temporary impairments of short-term investments available for sale, which affect interest income (expense), net;

•	valuation of other long-lived assets and goodwill, which affects depreciation and impairment of long-lived assets, impairment of goodwill and apportionment of goodwill related to divestitures;

•	potential costs of litigation, which affect operating expenses;

•	valuation of deferred income taxes, which affects income tax expense (benefit); and

•	stock-based compensation, which affects gross margin and operating expenses.

---

---

---

---

---

---

---

---

---

---

•	Caution concerning forward-looking statements. This section discusses how forward-looking statements made by us in the MD&A and elsewhere in this quarterly report are based on management’s present expectations about future events and are inherently susceptible to uncertainty and changes in circumstances.

•	Overview. This section provides an introductory overview and context for the discussion and analysis that follows in the MD&A.

•	Critical accounting policies. This section discusses those accounting policies that are both considered important to our financial condition and operating results and require significant judgment and estimates on the part of management in their application.

•	Results of operations. This section provides an analysis of our results of operations for the three and nine months ended December 31, 2015 and 2014. A brief description is provided of transactions and events that impact the comparability of the results being analyzed.

•	Liquidity and capital resources. This section provides an analysis of our cash position and cash flows, as well as a discussion of our financing arrangements and financial commitments.

---

---

---

---

---

---

---

---

---

---

•	our customers’ willingness to incorporate products based on the ARM® architecture, on which most of our new products are based, into their own products and systems;

•	our successful collaboration with our ecosystem and technology partners;

•	availability, quality, price, performance, power consumption, size and total cost of ownership of our products relative to competing products and technologies;

•	our accurate prediction of changing customer requirements;

•	the sufficiency and scale of our R&D budget and our timely development of new designs;

•	retention of key technical and design expertise, both internally and within third-party technology development partners;

•	timely qualification and certification of our products for use in electronic systems;

•	continued availability on commercially reasonable terms of the manufacturing services, technology components and tools that we purchase or license from third party suppliers;

•	commercial acceptance and production of the electronic systems into which our products are incorporated;

•	our customer service and support capabilities and responsiveness;

•	successful development of relationships with existing and potential new customers;

•	maintaining compliance and compatibility with new and changing industry standards and requirements;

•	maintaining close working relationships with key customers so that they will design our products into their future products; and

•	our ability to develop, gain access to and use leading technologies in a cost-effective and timely manner.

---

•	the scale and depth of our R&D, sales and marketing budgets and related resources, as compared to our competitors;

•	our ability to partner with original equipment manufacturer, or OEM, ecosystem and channel partners who are successful in the market;

•	success in designing and subcontracting the manufacture of new products that implement new technologies;

•	product quality, interoperability, reliability, performance and certification;

•	procurement expenses, supply chain economies of scale, and production efficiency, as compared to our larger competitors:

•	our ability to attract and retain key engineering, operations, sales and marketing employees and management;

•	pricing decisions or other actions taken by competitors;

---

•	customer support;

•	time-to-market;

•	price;

•	production efficiency;

•	design wins;

•	expansion of production of our products for particular systems manufacturers;

•	end-user acceptance of the systems manufacturers' products;

•	market acceptance of competitors' products; and

•	general economic conditions.

•

pricing of foundry services and of other supply chain services such as assembly, packaging and testing, from vendors such as Taiwan Semiconductor Manufacturing Company Ltd. ("TSMC"), GlobalFoundries, Inc. (which recently took over foundry services previously provided to us by International Business Machines Corporation), Advanced Semiconductor Engineering, Inc. ("ASE") and Siliconware Precision Industries Co. Ltd. ("SPIL");

•	reduced control over the supply chain process, delivery schedules and quality;

•	potentially inadequate manufacturing yields and excessive costs;

•	the risks associated with transitioning our manufacturing supply from one foundry or other supplier to another, which may be extremely difficult to accomplish, particularly on short notice and when cutting-edge process technologies are involved;

•	our ability to retain key personnel with specialized knowledge of our products and processes;

•	difficulties selecting and integrating new subcontractors;

•	the potential lack of adequate capacity at the foundry during periods of high demand, resulting in significant increases in lead time requirements and production delays, which can be expected to cause difficulties with our customers, including reduced revenues and higher expenses;

---

•	increased risk of excess and obsolete inventory charges due to the higher level of inventories in response to the increased lead times;

•	limited warranties on products supplied to us, which may not match the warranties that our customers require from us;

•	potential instability and business disruption in countries where third-party manufacturers or distributors are located;

•	potential misappropriation of our intellectual property; and

•	potential foundry shortages when we commence volume manufacturing of new products, especially those with 28nm and anticipated smaller geometry technologies or using more complicated manufacturing process technologies such as FinFET, which could delay the supply of products to our customers.

---

---

•	market acceptance of our products and our customers' products, including without limitation any failure of our X-Gene, X-Weave or HeliX product families to be commercially accepted within the time frames and at the levels we anticipate;

•	fluctuations in the timing and amount of customer requests for product shipments;

•	the reduction, rescheduling or cancellation of orders by customers, including without limitation as a result of slowing demand for our products or our customers' products, over-ordering or double booking of our products or our customers' products, or agreements with customers to accelerate, delay, increase or decrease previously anticipated orders;

•	changes in the timing and amounts of shipments due to our decision to phase out a particular product, which often results in near-term “last-time-buy” orders for the “end-of-life” product that would otherwise have been placed and shipped in later periods;

•	changes in the mix of product orders;

•	the gain or loss of one or more key customers or their key customers, or significant changes in the financial condition of one or more of our key customers or their key customers;

•	our ability to introduce, certify and deliver new products and technologies, including without limitation our X-Gene, X-Weave and HeliX products, on a timely basis;

•	the announcement or introduction of new products and technologies by our competitors;

•	competitive pressures on selling prices;

•	the ability of our customers to obtain components from their other suppliers;

•	risks associated with our or our customers' dependence on third-party manufacturing and supply relationships;

•	increases in the costs of technology and architecture licenses, mask sets and products, including without limitation with respect to smaller or more sophisticated process technologies such as FinFET, or the discontinuance of products, licenses, services or components by our suppliers;

•	the amounts and timing of meeting the specifications and expense recovery on non-recurring engineering projects;

•	the amounts and timing of costs associated with warranties, product returns and customer indemnification claims;

•	the impact of potential claims asserting infringement of third party patent or misappropriation of third party IP rights;

•	the amounts and timing of investments in R&D;

•	the product lifecycle and recoverability of architectural licenses, technology access fees and mask set costs;

---

•	revenue and margin fluctuations depending on the timing and amount of any IP licensing or sale transactions that we may undertake;

•	the amounts and timing of the costs associated with payroll taxes related to stock option exercises or settlement of restricted stock units;

•	the impact of potential one-time charges related to purchased intangibles;

•	the impact on interest income of a significant use of our cash for an acquisition, stock repurchase or other purpose;

•	the effects of changes in interest rates or credit worthiness on the value and yield of our short-term investment portfolio;

•	the effects of changes in accounting standards; and

•	the availability of ecosystem partners.

•	shortages of raw materials or production capacity constraints that lead our suppliers to allocate available supplies or capacity to their other customers, which may disrupt our ability to meet our production obligations;

•	our customers experiencing shortages from their suppliers, which may cause them to delay orders or deliveries of our products;

•	delays in the availability of our products or our customers' products;

•	delays in the availability of the software elements from third party vendors and ecosystem partners that may cause delays in customers' use of our hardware products, resulting in further delays in bringing our products to market;

•	the reduction, rescheduling or cancellation of customer orders, including without limitation agreements with customers to delay the timing or decrease the size of orders, resulting in decreased near-term revenues from the affected products, or to accelerate the timing or increase the size of orders, resulting in reduced revenues from those products in later periods;

•	declines in the average selling prices of our products;

•	delays in the introduction of new products, or lower than expected demand for new products;

•	delays when our customers are transitioning from old architectures, technologies and products to new architectures, technologies and products;

•	a decrease in demand for our products or our customers' products due to technological changes, industry consolidation, competitive developments, trends in our customers’ businesses or other factors;

•	a decline in the financial condition or liquidity of our customers or their customers;

•	the failure of our products to be qualified in our customers' systems or certified by our customers;

•	excess inventory of our products held by our customers, resulting in a reduction in their order patterns as they work through such excess inventory;

•	decisions to phase out or “end-of-life” particular products, which may result in higher near-term revenues due to customers’ final, “last-time-buy” orders, but a cessation of revenues from those products in later periods;

•	fabrication, test, product yield, or assembly constraints for our products that adversely affect our ability to meet our production obligations;

•	the failure of one or more of our subcontract manufacturers to perform its obligations to us;

•	our failure to successfully integrate acquired companies, products and technologies; and

•	global economic and industry conditions.

---

---

---

•	customers may stop incorporating our products into their own products with limited notice to us;

•	customers or prospective customers may not incorporate our products into their future product designs;

•	the timing and success of new product introductions by customers;

•	some of our customers may reduce or eliminate future purchase orders or design wins placed with us as an adverse reaction to our having sold patents to third parties that thereafter asserted the acquired patents in infringement actions brought against such customers, or due to other adverse intellectual property developments;

•	sales of customer product lines incorporating our products may rapidly decline or such product lines may be phased out;

•	our agreements with customers typically are non-exclusive and do not require them to purchase a minimum quantity of our products;

•	many of our customers have pre-existing relationships or may establish relationships with our current or potential competitors that may cause our customers to switch from using our products to using competing products;

•	some of our OEM customers may develop products internally that would replace our products;

•	we may not be able to successfully develop relationships with additional network equipment vendors;

•	our relationships with some of our larger customers may deter other potential customers (who compete with these customers) from buying our products; and

•	the impact of terminating certain sales or support personnel as a result of our workforce reduction or otherwise.

---

---

•	diversion of management's attention from our core businesses;

•	both expected and unanticipated adverse effects from the loss of technologies, patents and other intellectual property and personnel relating to divested subsidiaries, product lines and businesses;

•	adverse effects on existing business relationships with suppliers and customers;

•	costs associated with acquisitions, investments and divestitures;

•	difficulties associated with combining, integrating or separating acquired or divested operations, products or technologies;

•	failure to integrate or potential loss of key employees, particularly those of the acquired companies;

•	potential difficulties resulting from the divestiture of business operations, with respect to protecting the confidentiality of proprietary information and trade secrets not subject to the divestiture;

•	difficulties and risks associated with the methods, estimates and judgments we use in applying critical accounting policies, such as the methods and judgments we used in valuing the Veloce merger consideration, which affected our R&D expense in certain periods in fiscal 2014 and 2015;

•	difficulty in completing an acquired company's in-process research or development projects;

•	customer dissatisfaction or performance problems with an acquired company's products or services;

•	ability of the acquired companies to meet their financial projections and the effect of divesting subsidiaries and businesses on our revenues and margins.

•	issue stock that would dilute, in some cases significantly, our current stockholders' percentage ownership;

•	use a significant portion of our cash reserves or incur debt;

•	assume liabilities, including unanticipated third-party litigation and other unknown liabilities and unanticipated costs, events or circumstances;

•	incur adverse tax consequences;

•	incur amortization or impairment expenses related to goodwill and other intangible assets, depreciation and deferred compensation; and

•	incur large one-time charges and immediate write-offs.

---

•	foreign currency exchange fluctuations to the extent that this impacts our customers' purchasing power;

•	changes in regulatory requirements;

•	tariffs, rising protectionism and other trade barriers;

•	timing and availability of export licenses;

•	political and economic instability;

•	natural disasters;

•	increased exposure to liability under U.S and foreign anti-corruption laws and regulations;

•	difficulties in staffing and managing foreign operations;

•	difficulties in managing distributors;

•	reduced or uncertain protection for intellectual property rights in some countries;

•	longer payment cycles and difficulties in collecting accounts receivable in some countries;

•	burdens of complying with a wide variety of complex foreign laws and treaties;

•	potentially adverse tax consequences; and

•	uncertain economic conditions that may worsen or sustain improvements which trail those in the United States.

---

•	delays in development, manufacture and roll-out of new products;

•	additional development costs;

•	loss of, or delays in, market acceptance;

•	diversion of technical and other resources from our other development efforts;

•	claims by our customers or others against us; and

•	loss of credibility with our current and prospective customers.

---

---

---

---

•	having information about our products and technologies subpoenaed, and our employees deposed, in patent litigation between other third parties;

•	demands that we enter into expensive licenses of third party patent portfolios in order to avoid being named as a defendant in future IP infringement suits;

•	claims, contractual or otherwise, demanding that we indemnify or reimburse customers or end users of our products

•	demands from customers that we enter into “springing licenses” that prospectively grant such customers and related parties automatic license rights to any patents we sell or otherwise divest control over in specified transactions.

---

•	fluctuations in our anticipated or actual operating results;

•	our announcement of actual results or financial outlook that are higher or lower than market or analyst expectations;

•	changes in the economic performance or market valuations of other semiconductor companies or companies perceived by investors to be comparable to us;

•	announcements or introductions of new products by us or our competitors;

•	fluctuations in the anticipated or actual operating results or growth rates of our customers, peers or competitors;

•	technological innovations or setbacks by us or our competitors;

•	conditions in the semiconductor, communications or information technology markets;

•	the commencement or outcome of litigation or governmental investigations;

•	changes in ratings and estimates of our performance, or loss of coverage, by securities analysts;

•	positive or negative commentary about our business or prospects by industry bloggers and journalists;

•	volume fluctuations due to inconsistent trading volume levels of our shares;

•	announcements of merger, acquisition or financing transactions;

•	management or Board of Director changes;

•	our inclusion in certain stock indices; and

•	general economic and market conditions.

•	the ability of the board of directors to issue up to 2.0 million shares of “blank check” preferred stock with terms designed to prevent or delay a takeover attempt, as described further below;

•	the prohibition of cumulative voting in the election of directors, which would otherwise allow less than a majority of stockholders to elect director candidates;

•	the requirement for advance notice for nominations of directors for election to the board or for proposing matters that can be acted upon at a stockholders' meeting;

•	the ability of the board of directors to alter our bylaws without obtaining stockholder approval;

•	the requirement that any stockholder derivative actions and certain other intra-corporate disputes be litigated solely and exclusively in Delaware state court;

•	the right of the board of directors to elect a director to fill a vacancy created by the expansion of the board of directors; and

•	the prohibition of the right of stockholders to call a special meeting of stockholders.

---

---

---

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

(a)	Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b)	Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c)	Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d)	Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

(a)	All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b)	Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

1.	This Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2015 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

1.	This Quarterly Report on Form 10-Q for the quarterly period ended December 31, 2015 (the “Report”) fully complies with the requirements of Section 13(a) or Section 15(d) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”).

2.	The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

v3.3.1.900

Document and Entity Information - shares	9 Months Ended
	Dec. 31, 2015	Jan. 29, 2016
Document and Entity Information [Abstract]
Entity Registrant Name	APPLIED MICRO CIRCUITS CORP
Entity Central Index Key	0000711065
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Dec. 31, 2015
Document Fiscal Year Focus	2016
Document Fiscal Period Focus	Q3
Current Fiscal Year End Date	--03-31
Entity Filer Category	Accelerated Filer
Entity Common Stock, Shares Outstanding		83,537,389

v3.3.1.900

Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015	[1]
Current assets:
Cash and cash equivalents	$ 18,770	$ 36,495
Short-term investments	57,673	38,863
Accounts receivable, net	12,452	12,407
Inventories	19,692	23,514
Other current assets	14,578	16,840
Total current assets	123,165	128,119
Property and equipment, net	13,348	16,749
Goodwill	11,425	11,425
Other assets	1,626	2,570
Total assets	149,564	158,863
Current liabilities:
Accounts payable	12,876	13,896
Accrued payroll and other accrued liabilities	4,161	3,770
Veloce accrued liability	6,617	5,742
Other accrued liabilities	8,983	7,644
Deferred revenue	353	415
Total current liabilities	32,990	31,467
Non-current liabilities	$ 781	$ 4,291
Commitments and contingencies (Note 7)
Stockholders’ equity:
Preferred stock, $0.01 par value: Authorized shares - 2,000, none issued and outstanding	$ 0	$ 0
Common stock, $0.01 par value: Authorized shares - 375,000 at December 31, 2015 and March 31, 2015; Issued and outstanding shares - 83,537 at December 31, 2015 and 80,816 at March 31, 2015	835	808
Additional paid-in capital	6,051,474	6,032,604
Accumulated other comprehensive loss	(10,031)	(7,486)
Accumulated deficit	(5,926,485)	(5,902,821)
Total stockholders’ equity	115,793	123,105
Total liabilities and stockholders’ equity	$ 149,564	$ 158,863
[1] The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

v3.3.1.900

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2015	Mar. 31, 2015
Statement of Financial Position [Abstract]
Preferred stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (shares)	2,000,000	2,000,000
Preferred stock, shares issued (shares)	0	0
Preferred stock, shares outstanding (shares)	0	0
Common stock, par value (in Dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (shares)	375,000,000	375,000,000
Common stock, shares issued (shares)	83,537,000	80,816,000
Common stock, shares outstanding (shares)	83,537,000	80,816,000

v3.3.1.900

Condensed Consolidated Statements of Operations (Unaudited) - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Income Statement [Abstract]
Net revenues	$ 40,623	$ 36,747	$ 118,179	$ 127,964
Cost of revenues	18,241	14,842	52,805	52,815
Gross profit	22,382	21,905	65,374	75,149
Operating expenses:
Research and development	22,377	24,721	66,405	82,636
Selling, general and administrative	8,232	8,707	25,369	25,684
Amortization of purchased intangible assets	0	0	0	105
Restructuring	(29)	221	82	1,322
Total operating expenses	30,580	33,649	91,856	109,747
Operating loss	(8,198)	(11,744)	(26,482)	(34,598)
Realized gain on short-term investments and interest income, net	148	485	2,024	1,214
Other income (expense), net	21	(10)	54	(2,536)
Loss before income taxes	(8,029)	(11,269)	(24,404)	(35,920)
Income tax provision (benefit)	170	862	(740)	993
Net loss	$ (8,199)	$ (12,131)	$ (23,664)	$ (36,913)	[1]
Basic and diluted net loss per share (in dollars per share)	$ (0.10)	$ (0.15)	$ (0.29)	$ (0.47)
Shares used in calculating basic and diluted net loss per share (in shares)	83,191	78,920	82,186	78,442
[1] The Statement of Cash Flows for the nine months ended December 31, 2014 reflects immaterial revisions to correct $0.3 million of outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities and $0.1 million of net realized gains on short-term investments previously classified as net cash used for operating activities to net cash provided by investing activities. As a result, net cash used for operating activities increased by $0.4 million and net cash used for investing activities decreased by the corresponding amount.

v3.3.1.900

Condensed Consolidated Statements of Comprehensive Loss (unaudited) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Net loss		$ (8,199)	$ (12,131)	$ (23,664)	$ (36,913)	[1]
Other comprehensive loss, net of tax:
Unrealized gain (loss) on investments	[2]	(263)	(78)	(2,112)	218
Loss on foreign currency translation		(63)	(159)	(433)	(374)
Other comprehensive loss, net of tax		(326)	(237)	(2,545)	(156)
Total comprehensive loss		$ (8,525)	$ (12,368)	$ (26,209)	$ (37,069)
[1] The Statement of Cash Flows for the nine months ended December 31, 2014 reflects immaterial revisions to correct $0.3 million of outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities and $0.1 million of net realized gains on short-term investments previously classified as net cash used for operating activities to net cash provided by investing activities. As a result, net cash used for operating activities increased by $0.4 million and net cash used for investing activities decreased by the corresponding amount. [2] The amounts reclassified from accumulated other comprehensive loss and recorded in net realized gain on short-term investments and interest income, net in the Condensed Consolidated Statement of Operations relating to sale of short-term investments were zero and $1.5 million for the three and nine months ended December 31, 2015, respectively, and $0.1 million each for the three and nine months ended December 31, 2014. Refer to Note 2, Certain Financial Statement Information, to the Condensed Consolidated Financial Statements for additional details.

v3.3.1.900

Condensed Consolidated Statements of Comprehensive Loss (unaudited) (Parenthetical) - USD ($)	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Statement of Comprehensive Income [Abstract]
Reclassification adjustment from AOCI to earnings, short term investments	$ 0	$ 100,000	$ 1,500,000	$ 100,000

v3.3.1.900

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2015		Dec. 31, 2014	[1]
Adjustments to reconcile net loss to net cash provided by (used for) operating activities:
Net loss	$ (23,664)		$ (36,913)
Depreciation	5,699		6,598
Amortization of purchased intangible assets	0		105
Amortization of bond premium	429		0
Stock-based compensation expense	18,167		14,303
Veloce acquisition consideration	0		7,140
Gain on short-term Investments and other, net	(1,588)		(101)
Non cash restructuring charges	0		14
Impairment of a strategic investment	0		2,500
Tax effect on other comprehensive loss	0		(34)
Changes in operating assets and liabilities:
Accounts receivable	(45)		5,931
Inventories	3,849		(5,271)
Other assets	2,863		(736)
Accounts payable	(1,366)		(3,719)
Accrued payroll and other accrued liabilities	338		(927)
Veloce accrued liability	(99)		(8,981)
Deferred revenue	(62)		(188)
Net cash provided by (used for) operating activities	4,521		(20,279)
Investing activities:
Proceeds from sales and maturities of short-term investments	58,227		5,198
Purchases of short-term investments	(78,021)		(2,722)
Proceeds from sale of property and equipment	31		1
Purchases of property and equipment	(2,039)		(7,291)
Proceeds from sale of TPack	0		3,353
Net cash used for investing activities	(21,802)		(1,461)
Financing activities:
Proceeds from issuance of common stock	1,243		1,890
Funding of restricted stock units withheld for taxes	(1,687)		(1,609)
Net cash provided by (used for) financing activities	(444)		281
Net decrease in cash and cash equivalents	(17,725)		(21,459)
Cash and cash equivalents at beginning of year	36,495	[2]	71,539
Cash and cash equivalents at end of period	18,770		50,080
Supplementary cash flow disclosures:
Cash paid for income taxes	519		643
Common stock issued for Veloce merger consideration	$ 2,869		$ 872
[1] The Statement of Cash Flows for the nine months ended December 31, 2014 reflects immaterial revisions to correct $0.3 million of outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities and $0.1 million of net realized gains on short-term investments previously classified as net cash used for operating activities to net cash provided by investing activities. As a result, net cash used for operating activities increased by $0.4 million and net cash used for investing activities decreased by the corresponding amount. [2] The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

v3.3.1.900

Condensed Consolidated Statements of Cash Flows (Unaudited) (Parenthetical) $ in Thousands	9 Months Ended
	Dec. 31, 2014 USD ($)
Prior Period Adjustments Restatement [Line Items]
Increase(decrease) in outstanding payables related to purchases of property and equipment	$ 7,291	[1]
Increase(decrease) in net realized gains on short-term investments	5,198	[1]
Increase in net cash provided by operating activities	(20,279)	[1]
Decrease in net cash provided by investing activities	1,461	[1]
Previously Reported [Member]
Prior Period Adjustments Restatement [Line Items]
Increase(decrease) in outstanding payables related to purchases of property and equipment	(300)
Increase(decrease) in net realized gains on short-term investments	(100)
Restatement Adjustment [Member]
Prior Period Adjustments Restatement [Line Items]
Increase(decrease) in outstanding payables related to purchases of property and equipment	300
Increase(decrease) in net realized gains on short-term investments	100
Increase in net cash provided by operating activities	400
Decrease in net cash provided by investing activities	$ 400
[1] The Statement of Cash Flows for the nine months ended December 31, 2014 reflects immaterial revisions to correct $0.3 million of outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities and $0.1 million of net realized gains on short-term investments previously classified as net cash used for operating activities to net cash provided by investing activities. As a result, net cash used for operating activities increased by $0.4 million and net cash used for investing activities decreased by the corresponding amount.

v3.3.1.900

Summary of Significant Accounting Policies	9 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES	THE COMPANY AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Overview Applied Micro Circuits Corporation (the "Company") is a global leader in silicon solutions for next-generation cloud infrastructure and data centers, as well as connectivity products for edge, metro and long-haul communications equipment. Basis of Presentation The Condensed Consolidated Financial Statements include all the accounts of the Company's and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company prepared the accompanying unaudited Condensed Consolidated Financial Statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). In management’s opinion, the unaudited Condensed Consolidated Financial Statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to fairly present the Company's financial position, results of operations and cash flows. Interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the Consolidated Financial Statements and notes thereto in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2015. Commencing the quarter ended December 31, 2015, the Company recognizes revenue from development agreements upon completion and acceptance by the customer of contract deliverables or as services are provided, depending on the terms of the arrangement. Revenue is deferred for any amounts billed or received prior to completion of milestones or delivery of services. As the Company retains the intellectual property, or IP, generated from these development agreements, costs related to these arrangements are included in Research and Development ("R&D"), expense. Use of Estimates The preparation of financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to its: • capitalized mask sets including their useful lives, which affect cost of goods sold and property and equipment or R&D expenses, if not capitalized; • inventory valuation, warranty liabilities and revenue reserves, which affect cost of sales, gross margin, and revenues; • allowance for doubtful accounts, which affects operating expenses; • unrealized losses or other-than-temporary impairments of short-term investments available for sale, which affect interest income (expense), net; • valuation of other long-lived assets and goodwill, which affects depreciation and impairment of long-lived assets, impairment of goodwill and apportionment of goodwill related to divestitures; • potential costs of litigation, which affect operating expenses; • valuation of deferred income taxes, which affects income tax expense (benefit); and • stock-based compensation, which affects gross margin and operating expenses. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from management’s estimates. To the extent there are material differences between the estimates and actual results, future results of operations will be affected. Concentrations of Credit Risk and Significant Customers The Company's cash, cash equivalents, short-term investments and accounts receivable are potentially subject to concentration of credit risk. Cash and cash equivalents may be redeemable upon demand and are maintained with several financial institutions that management believes are of high credit quality and therefore bear minimal credit risk. The Company's accounts receivables are derived from revenue earned from customers located around the world. The Company mitigates collection risks from its customers by performing regular credit evaluations of customers' financial condition and payment history and requiring collateral, such as letters of credit, corporate guarantee or prepayment, in certain circumstances. The Company sells its products primarily through direct sales force and distributors. Based on direct shipments, 3 customers individually each accounted for at least 10% of total net revenues during the three months ended December 31, 2015 and 2014 and 2 customers individually each accounted for at least 10% of total net revenues during the nine months ended December 31, 2015 and 2014. The Company expects that its largest customers collectively will continue to account for a substantial portion of its net revenue for the foreseeable future. New Accounting Pronouncements In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2014-15, "Presentation of Financial Statements - Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern", which requires an entity's management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or within one year after the date that the financial statements are available to be issued, when applicable. The standard is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating this new standard, and after adoption, it will incorporate this guidance in its assessment of going concern. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers", which will supersede most of the existing revenue recognition guidance under U.S. GAAP. This ASU requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted but adoption on the original effective date is permitted. The ASU allows for either full retrospective or modified retrospective adoption. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures. In November 2015, the FASB issued ASU No. 2015-17, "Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes" to simplify the presentation of deferred taxes in the statement of financial position. The new guidance requires that deferred tax assets and liabilities be classified as non-current in a classified balance sheet. This ASU is effective for fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. Earlier adoption is permitted as of the beginning of an interim or annual reporting period, and may be applied either prospectively, for all deferred tax assets and liabilities, or retrospectively. The Company is currently evaluating the potential effect of this ASU on its financial position.

v3.3.1.900

Certain Financial Statement Information	9 Months Ended
	Dec. 31, 2015
Certain Financial Statement Information [Abstract]
CERTAIN FINANCIAL STATEMENT INFORMATION	CERTAIN FINANCIAL STATEMENT INFORMATION Accounts receivable, net:     December 31, 2015   March 31, 2015     (In thousands) Accounts receivable   $ 12,732   $ 12,709 Less: allowance for bad debts   (280 )   (302 )     $ 12,452   $ 12,407 Inventories:     December 31, 2015   March 31, 2015     (In thousands) Finished goods   $ 10,405   $ 15,310 Work in process   6,508   5,377 Raw materials   2,779   2,827     $ 19,692   $ 23,514 Other current assets:     December 31, 2015   March 31, 2015     (In thousands) Prepaid expenses   $ 12,284   $ 14,847 Executive deferred compensation assets   985   1,004 Other   1,309   989     $ 14,578   $ 16,840 Property and equipment:     Useful Life   December 31, 2015   March 31, 2015     (In years)   (In thousands) Machinery and equipment   3-5   $ 38,244   $ 37,286 Leasehold improvements   1-5   7,528   9,909 Computers, office furniture and equipment   3-5   34,444   32,902         80,216   80,097 Less: accumulated depreciation       (66,868 )   (63,348 )         $ 13,348   $ 16,749 Other accrued liabilities:     December 31, 2015   March 31, 2015     (In thousands) Employee related liabilities   $ 1,377   $ 1,454 Executive deferred compensation   1,017   1,025 Accrued bonus   1,768   39 Income taxes   330   1,311 Other   4,491   3,815     $ 8,983   $ 7,644 Short-term investments: The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument (in thousands):   December 31, 2015   March 31, 2015   Amortized Cost   Gross Unrealized   Estimated Fair Value   Amortized Cost   Gross Unrealized   Estimated Fair Value   Gains   Losses   Gains   Losses   Cash $ 16,299   $ —   $ —   $ 16,299   $ 33,936   $ —   $ —   $ 33,936 Cash equivalents 2,471   —   —   2,471   2,559   —   —   2,559 U.S. Treasury securities and agency bonds 17,855   —   (54 )   17,801   1,230   —   —   1,230 Corporate bonds 25,957   18   (63 )   25,912   10,772   28   (6 )   10,794 Asset-backed and mortgage-backed securities 11,948   1   (50 )   11,899   —   15   —   15 Municipal bonds 2,071   —   (10 )   2,061   —   —   —   — Mutual funds —   —   —   —   24,895   1,955   (59 )   26,791 Preferred stock —   —   —   —   11   22   —   33   $ 76,601   $ 19   $ (177 )   $ 76,443   $ 73,403   $ 2,020   $ (65 )   $ 75,358 Reported as:                               Cash and cash equivalents             $ 18,770               $ 36,495 Short-term investments available-for-sale             57,673               38,863               $ 76,443               $ 75,358   The established guidelines for measuring fair value and expanded disclosures regarding fair value measurements are defined as a three-level valuation hierarchy for disclosure of fair value measurements as follows: Level 1 — Inputs are unadjusted, quoted prices in active markets for identical assets or liabilities at the measurement date. Level 2 — Inputs (other than quoted market prices included in Level 1) are either directly or indirectly observable for the asset or liability through correlation with market data at the measurement date and for the duration of the instrument’s anticipated life. Level 3 — Inputs reflect management’s best estimate of what market participants would use in pricing the asset or liability at the measurement date. Consideration is given to the risk inherent in the valuation technique and the risk inherent in the inputs to the model. Valuation of instruments includes unobservable inputs to the valuation methodology that are significant to the measurement of the fair value of assets or liabilities. The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument measured at fair value on a recurring basis (in thousands):     December 31, 2015   March 31, 2015     Level 1   Level 2   Level 3   Total   Level 1   Level 2   Level 3   Total Cash   $ 16,299   $ —   $ —   $ 16,299   $ 33,936   $ —   $ —   $ 33,936 Cash equivalents   2,071   400   —   2,471   2,559   —   —   2,559 U.S. Treasury securities and agency bonds   17,801   —   —   17,801   1,230   —   —   1,230 Corporate bonds   —   25,912   —   25,912   —   10,794   —   10,794 Asset-backed and mortgage-backed securities   —   11,899   —   11,899   —   15   —   15 Municipal bonds   —   2,061   —   2,061   —   —   —   — Mutual funds   —   —   —   —   26,791   —   —   26,791 Preferred stock   —   —   —   —   —   33   —   33     $ 36,171   $ 40,272   $ —   $ 76,443   $ 64,516   $ 10,842   $ —   $ 75,358 There were no significant transfers in and out of Level 1 and Level 2 fair value measurement categories during the three and nine months ended December 31, 2015 and 2014. The following is a summary of the cost and estimated fair values of available-for-sale securities with stated maturities, which include U.S. Treasury securities and agency bonds, corporate bonds, asset-backed and mortgage-backed securities and municipal bonds, by contractual maturity (in thousands):     December 31, 2015     Cost   Estimated Fair Value Less than 1 year   $ 15,500   $ 15,485 Mature in 1 – 2 years   31,021   30,908 Mature in 3 – 5 years   11,310   11,280 Mature after 5 years   —   —     $ 57,831   $ 57,673 The following is a summary of gross unrealized losses (in thousands): As of December 31, 2015   Less Than 12 Months of Unrealized Losses   12 Months or More of Unrealized Losses   Total     Estimated Fair Value   Gross Unrealized Losses   Estimated Fair Value   Gross Unrealized Losses   Estimated Fair Value   Gross Unrealized Losses U.S. Treasury securities and agency bonds   $ 17,260   $ (54 )   $ —   $ —   $ 17,260   $ (54 ) Corporate bonds   18,243   (63 )   —   —   18,243   (63 ) Asset-backed and mortgage-backed securities   10,793   (50 )   —   —   10,793   (50 ) Municipal bonds   1,898   (10 )   —   —   1,898   (10 )     $ 48,194   $ (177 )   $ —   $ —   $ 48,194   $ (177 ) As of March 31, 2015   Less Than 12 Months of Unrealized Losses   12 Months or More of Unrealized Losses   Total     Estimated Fair Value   Gross Unrealized Losses   Estimated Fair Value   Gross Unrealized Losses   Estimated Fair Value   Gross Unrealized Losses Corporate bonds   $ 878   $ (6 )   $ —   $ —   $ 878   $ (6 ) Mutual funds   14,592   (17 )   475   (42 )   15,067   (59 )     $ 15,470   $ (23 )   $ 475   $ (42 )   $ 15,945   $ (65 ) Realized gain on short-term investments and interest income, net (in thousands):     Three Months Ended December 31,   Nine Months Ended December 31,     2015   2014   2015   2014 Net realized gain (loss) on short-term investments   $ (2 )   $ 123   $ 1,557   $ 123 Interest income, net   150   362   467   1,091     $ 148   $ 485   $ 2,024   $ 1,214 Net loss per share: Shares used in basic net loss per share are computed using the weighted average number of common shares outstanding during each period. Shares used in diluted net loss per share include the dilutive effect of common shares potentially issuable upon the exercise of stock options and vesting of restricted stock units ("RSUs"). For the three and nine months ended December 31, 2015 and 2014, the Company recorded a net loss. As such, all outstanding potential common shares were excluded from the diluted earnings per share computation. The following potentially dilutive common shares are excluded from the computation of net loss per share (in thousands):     December 31, 2015   December 31, 2014 Outstanding stock options   1,650   1,882 Outstanding RSUs   4,752   4,642 ESPP shares   365   350     6,767   6,874

v3.3.1.900

Restructuring Charges	9 Months Ended
	Dec. 31, 2015
Restructuring and Related Activities [Abstract]
RESTRUCTURING CHARGES	RESTRUCTURING CHARGES In January 2015, the Company implemented a restructuring plan to reorganize its operations and reduce its workforce and related operating expenses in order to increase its operating efficiencies. This plan eliminated approximately 40 positions, or approximately 7%, of headcount. The Company completed this plan at the end of the quarter ended September 30, 2015 and incurred total restructuring charges of $4.2 million. The following table sets forth a summary of restructuring activities related to the Company's restructuring plan described above (in thousands):     Workforce Reduction   Operating Lease Commitments   Other   Total Liability, March 31, 2015   $ 449   $ 113   $ 15   $ 577 Restructuring charges   80   —   2   82 Cash payments   (286 )   (61 )   (9 )   (356 ) Non-cash items   (22 )   12   (8 )   (18 ) Liability, December 31, 2015   $ 221   $ 64   $ —   $ 285

v3.3.1.900

Veloce	9 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
VELOCE	VELOCE In June 2012, the Company completed its acquisition of Veloce Technologies, Inc. ("Veloce") which had been developing specific ARM-based technology for the Company. The total purchase consideration for Veloce was $178.5 million, the payment of which has been subject to the completion of certain development milestones and vesting requirements. For accounting purposes, the costs incurred in connection with the development milestones relating to Veloce were considered compensatory and recognized as R&D expense in the Condensed Consolidated Statements of Operations. Veloce completed the milestones as of March 31, 2014 and the total consideration of $178.5 million has been recognized as R&D expense as of March 31, 2015. The following table summarizes the cash payment and stock issuance activities during the three and nine months ended December 31, 2015 and 2014 as part of the above arrangement (in thousands):   Three Months Ended December 31,   Nine Months Ended December 31,   2015   2014   2015   2014 Cash payments $ 9   $ 1,482   $ 99   $ 8,981 Value of common stock issued 1   257   2,869   872 Total payments $ 10   $ 1,739   $ 2,968   $ 9,853 Shares of common stock issued —   39   517   116 As of December 31, 2015, $171.9 million of the total Veloce consideration has been paid and the Company expects that an additional $2.2 million will be paid in cash and stock by March 31, 2016. The $171.9 million paid to date includes $89.4 million in cash and the issuance of 11.2 million shares of common stock valued at $82.5 million. The consideration not yet paid of $6.6 million can be settled in cash or common stock (or a combination of cash and stock) at the Company's election and is classified as short-term in the Condensed Consolidated Balance Sheet as of December 31, 2015.

v3.3.1.900

Stockholders' Equity	9 Months Ended
	Dec. 31, 2015
Equity [Abstract]
STOCKHOLDERS' EQUITY	STOCKHOLDERS’ EQUITY  Stock Options The Company has granted stock options to employees and non-employee directors under several plans. These option plans include two stockholder-approved plans (1992 Equity Incentive Plan and 2011 Equity Incentive Plan) and one plan not approved by stockholders (2000 Equity Incentive Plan). A summary of the Company's stock option activities and related information during the nine months ended December 31, 2015 is as follows:     Number of Shares (thousands)   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Term (years)   Aggregate Intrinsic Value (millions)   Outstanding at the beginning of the year   1,794   $ 9.15           Granted   —   —         Exercised   (25 )   $ 5.23     — (1 ) Cancelled   (119 )   $ 10.91           Outstanding, vested and exercisable at the end of the period   1,650   $ 9.09   1.2   $ 0.1 (2 ) (1) The aggregate pre-tax intrinsic value is calculated as the difference between the market value on the date of exercise and the exercise price of the shares. (2) The aggregate pre-tax intrinsic value is calculated as the difference between the market value as of December 31, 2015 and the exercise price of the shares. The closing price of the Company’s common stock was $6.37 per share on December 31, 2015. Restricted Stock Units The Company has granted RSUs to employees and non-employee directors pursuant to its 1992 Equity Incentive Plan and 2011 Equity Incentive Plan. RSUs are share awards that, upon vesting, will deliver to the holder shares of the Company’s common stock. RSUs vest over varying terms, to a maximum of four years from the date of the grant.  In May and November 2013, May and October 2014 and November 2015, the Compensation Committee (the "Committee") authorized market-performance based RSUs ("MSUs"). The MSUs will be earned, if at all, based on the Company's Total Shareholder Return (“TSR”) compared to that of the Standard & Poor's Depositary Receipts (the "SPDR") S&P Semiconductor Index ("Index”) over a two-year performance period for half of the MSU award and a three-year performance period for the remaining half of the MSU award. The MSUs will vest between ranges of 0% and 150% or 0% and 175% based on the Company's relative TSR compared to the Index. Total grant-date fair value of these MSUs was $5.5 million, of which $2.6 million expired unvested as of December 31, 2015. The Company has compensation programs with respect to fiscal 2016 and 2017. The programs include time-based RSUs and financial or operational performance-based awards with payouts that ranges from 0% to 150% of pre-established target levels. Awards under these programs vest in fiscal 2016 through 2018 and can be paid out in common stock or cash. RSU activities during the nine months ended December 31, 2015 is set forth below (in thousands):   Number of Shares Outstanding at the beginning of the year 4,328 Awarded 3,406 Vested (2,202 ) Cancelled (780 ) Outstanding at the end of the period 4,752 The weighted average remaining contractual term for the RSUs outstanding as of December 31, 2015 was 1.2 years. As of December 31, 2015, the aggregate pre-tax intrinsic value of RSUs outstanding was $30.3 million. The aggregate pretax intrinsic value was calculated based on the closing price of the Company’s common stock of $6.37 on December 31, 2015. The aggregate pre-tax intrinsic value of RSUs vested during the nine months ended December 31, 2015 was $13.9 million. This intrinsic value represents the fair market value of the Company’s common stock on the date of release. Employee Stock Purchase Plan Under the Company's 2012 Employee Stock Purchase Plan, or ESPP, the Company reserved 3.8 million shares for issuance. Under the terms of the ESPP, eligible employees are entitled to purchase common stock, on a semi-annual basis, at a purchase price equal to 85% of the fair market value of the common stock on the first or last day of the offering period, whichever is lower. At December 31, 2015, 1.6 million shares were available for future issuance under the ESPP. Employees purchased 0.2 million shares at an average price of $4.46 and 0.2 million shares at an average price of $7.09 for the nine months ended December 31, 2015 and 2014, respectively. The intrinsic value of shares purchased during the nine months ended December 31, 2015 and 2014 was $0.4 million and $0.3 million, respectively. The intrinsic value is calculated as the difference between the market value on the date of purchase and the purchase price of the shares.

v3.3.1.900

Stock-Based Compensation	9 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
STOCK-BASED COMPENSATION	STOCK-BASED COMPENSATION Stock-based compensation cost is measured at the grant date based on the fair value of the award. The fair value of RSUs is estimated using the Company's stock price on the grant date. The fair value of options and employee stock purchase rights is estimated using the Black-Scholes model on the grant date. The Black-Scholes model determines the fair value of share-based payment awards based on assumptions including the Company's stock price on the date of grant, volatility over the term of the awards, actual and projected employee stock option exercise behaviors and risk free interest rate. The MSUs were valued using the Monte Carlo pricing model, which uses the Company's stock price, the Index value, expected volatilities of the Company's stock price and the Index, correlation coefficients and risk free interest rates to determine the fair value. The Company did not grant options during the nine months ended December 31, 2015 and 2014. The Company did not grant employee stock purchase rights during the three months ended December 31, 2015. The fair values of the employee stock purchase rights granted during the nine months ended December 31, 2015 and 2014 are estimated as of the grant date using the Black-Scholes option-pricing model with the following assumptions:   Nine Months Ended December 31,   2015   2014 Expected life (years) 0.5   0.5 Risk-free interest rate 0.1 %   0.1 % Volatility 57 %   57 % Weighted average fair value $ 1.80   $ 2.57 The weighted average grant-date fair value per share of the RSUs awarded was $6.87 and $5.01 during the three and nine months ended December 31, 2015, respectively, as compared to $5.82 and $8.20 during the three and nine months ended December 31, 2014, respectively. The weighted average grant-date fair value per share was calculated based on the fair market value of the Company’s common stock on the respective grant dates. The following tables summarize the allocation of the stock-based compensation expense (in thousands): Stock-based compensation expense by type of grant: Three Months Ended December 31,   Nine Months Ended December 31,   2015   2014   2015   2014 Stock options and stock purchase rights $ 352   $ 454   $ 848   $ 1,160 RSUs 5,800   4,428   17,347   13,148   6,152   4,882   18,195   14,308 Stock-based compensation capitalized to inventory (11 )   (25 )   (28 )   (5 ) Total $ 6,141   $ 4,857   $ 18,167   $ 14,303 Stock-based compensation expense by cost centers: Three Months Ended December 31,   Nine Months Ended December 31,   2015   2014   2015   2014 Cost of revenues $ 151   $ 97   $ 377   $ 226 Research and development 4,500   2,992   12,515   9,039 Selling, general and administrative 1,501   1,793   5,303   5,043   6,152   4,882   18,195   14,308 Stock-based compensation capitalized to inventory (11 )   (25 )   (28 )   (5 ) Total $ 6,141   $ 4,857   $ 18,167   $ 14,303 As of December 31, 2015, the amount of unrecognized stock-based compensation cost, net of estimated forfeitures, related to unvested stock-based awards was $33.4 million which will be recognized over a weighted average period of 1.2 years.

v3.3.1.900

Commitments and Contingencies	9 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	COMMITMENTS AND CONTINGENCIES Commitments The following table summarizes the Company's contractual operating leases and other purchase commitments as of December 31, 2015 (in thousands): Fiscal Years Ending March 31, Operating Leases   Purchase Commitments *   Total 2016 (remainder of year) $ 718   $ 22,277   $ 22,995 2017 2,350   10,814    13,164 2018 824   5,225    6,049 2019 472   378    850 Total minimum payments $ 4,364   $ 38,694    $ 43,058 * Includes open purchase orders with terms that generally allow us the option to cancel or reschedule the order, subject to various restrictions and limitations. Also includes the licensing fees relating to the Company's R&D efforts, including IP, technology, product design, test and verification tools, of $15.4 million. Warranty The Company's products typically carry a one-year warranty. The Company establishes reserves for estimated product warranty costs at the time revenue is recognized. Although the Company engages in extensive product quality programs and processes, its warranty obligation is affected by product failure rates, use of materials, and service delivery costs incurred in correcting any product failure. Historically, the Company’s warranty returns have not been material. Intellectual Property Indemnities The Company indemnifies certain customers and contract manufacturers against liability arising from third-party claims of IP rights infringement related to its products. These indemnities appear in development and supply agreements with customers as well as manufacturing service agreements with contract manufacturers and generally survive the expiration of the contract. Given that the amount of any potential liabilities related to such indemnities cannot be determined until an infringement claim has been made, the Company is unable to determine the maximum amount of losses that could be incurred related to such indemnifications. Guarantees and Indemnities In the normal course of business, the Company is occasionally required to provide other guarantees and indemnities for which it may be required to make future payments under specific circumstances. The amount of any potential liabilities related to such obligations cannot be accurately determined until a formal claim is filed. The Company maintains general and product liability insurance which may provide a source of recovery in the event of an indemnification claim. Legal Proceedings The Company is currently a party to certain legal proceedings, including those noted in this section. While the Company presently believes that the ultimate outcome of these proceedings, individually and in the aggregate, will not materially harm the Company's financial position, results of operations or cash flows, legal proceedings are subject to inherent uncertainties, unfavorable rulings or other events that could occur. In addition, legal proceedings are expensive to prosecute and defend against and can divert management attention and Company resources away from the Company's business objectives. Unfavorable resolutions could include monetary damages against the Company or injunctions or other restrictions on the conduct of the Company’s business, or preclude the Company from recovering the damages it seeks in legal proceedings it has commenced. It is also possible that the Company could conclude it is in the best interests of its stockholders, employees, and customers to settle one or more such matters, and any such settlement could include substantial payments or the surrender of rights to collect payments from third parties. However, the Company has not reached this conclusion with respect to any material matter at this time. In 1993, the Company was named as a Potentially Responsible Party (“PRP”) along with more than 100 other companies that used an Omega Chemical Corporation waste treatment facility in Whittier, California (the “Omega Site”). The U.S. Environmental Protection Agency (“EPA”) has alleged that Omega failed to properly treat and dispose of certain hazardous waste materials at the Omega Site. The Company is a member of a large group of PRPs, known as the Omega Chemical Site PRP Organized Group (“OPOG”), that has agreed to fund certain on-going remediation efforts relating to the Omega Site. Pursuant to a consent decree entered into between EPA and OPOG and approved by the U.S. District Court for the Central District of California (the “Court”), removal of waste materials from the Omega Site has been completed. Efforts to remediate the soil and groundwater at the Omega Site, as well as the extraction of chemical vapors from the soil and improving indoor air quality in and around the site, are still underway and are expected to be ongoing for several more years. In addition, OPOG and EPA are negotiating the remediation plan for a regional groundwater contamination plume allegedly originating at the Omega Site (the Operable Unit 2 or “OU2”). In December 2014, EPA and OPOG agreed upon the basic settlement terms and remediation actions for OU2 that will be set forth in a consent decree that once finalized will be filed with the Court. It is anticipated that Court approval of the consent decree will occur in fiscal year 2017, following which remediation of OU2 will commence. In December 2013, OPOG retained legal counsel to pursue claims against other PRPs for the regional groundwater contamination and, in December 2014, OPOG retained legal counsel to protect its interests in connection with the bankruptcy proceedings filed by an OPOG member. In November 2007, Angeles Chemical Company, located downstream from the Omega Site, filed a lawsuit (the “Angeles Litigation”) in the Court against OPOG and the PRPs for cost recovery and indemnification for future response costs allegedly resulting from OU2. In March 2008, the Court granted OPOG’s motion to stay the Angeles Litigation pending EPA’s determination of how to investigate and remediate the regional groundwater. In January 2012, as a result of challenges made by certain PRPs to the criteria previously used to allocate liability among OPOG members, and of the departure of certain PRPs from OPOG, OPOG approved changes to the cost allocation structure that resulted in an increase to the Company’s proportional allocation of liability. In addition, the subsequent departure or bankruptcy of one or more other PRPs from OPOG could have the effect of increasing the proportional liability of the remaining PRPs, including the Company. To date, the Company has remitted payments to OPOG covering its proportional allocation of liability for legal expenses and remediation costs, and the Company anticipates that its payment obligations relating to the Omega Site will increase once the OU2 consent decree is finalized. Notwithstanding such anticipated increases, the Company does not currently believe its total share of remediation-related expenses will be material to the Company’s financial statements, based on the Company’s approximately 0.5% contribution to the total waste tonnage sent to the site and current estimates of the potential aggregate remediation costs. Based on currently available information, the Company has a loss accrual that is not material and believes that the actual amount of its costs will not be materially different from the amount accrued. However, proceedings are ongoing and the eventual outcome of the clean-up efforts and the pending litigation matters is uncertain at this time. Based on currently available information, the Company does not believe that any eventual outcome will have a material adverse effect on its business or operations.

v3.3.1.900

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Dec. 31, 2015
Accounting Policies [Abstract]
Basis of Presentation	Basis of Presentation The Condensed Consolidated Financial Statements include all the accounts of the Company's and its wholly-owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. The Company prepared the accompanying unaudited Condensed Consolidated Financial Statements pursuant to the rules and regulations of the Securities and Exchange Commission (the “SEC”). In management’s opinion, the unaudited Condensed Consolidated Financial Statements reflect all adjustments (consisting only of normal recurring adjustments) necessary to fairly present the Company's financial position, results of operations and cash flows. Interim period operating results do not necessarily indicate the results that may be expected for any other interim period or for the full fiscal year. These financial statements and accompanying notes should be read in conjunction with the Consolidated Financial Statements and notes thereto in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2015. Commencing the quarter ended December 31, 2015, the Company recognizes revenue from development agreements upon completion and acceptance by the customer of contract deliverables or as services are provided, depending on the terms of the arrangement. Revenue is deferred for any amounts billed or received prior to completion of milestones or delivery of services. As the Company retains the intellectual property, or IP, generated from these development agreements, costs related to these arrangements are included in Research and Development ("R&D"), expense.
Use of Estimates	Use of Estimates The preparation of financial statements in accordance with U.S. generally accepted accounting principles, or GAAP, requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of net revenue and expenses in the reporting period. The Company regularly evaluates estimates and assumptions related to its: • capitalized mask sets including their useful lives, which affect cost of goods sold and property and equipment or R&D expenses, if not capitalized; • inventory valuation, warranty liabilities and revenue reserves, which affect cost of sales, gross margin, and revenues; • allowance for doubtful accounts, which affects operating expenses; • unrealized losses or other-than-temporary impairments of short-term investments available for sale, which affect interest income (expense), net; • valuation of other long-lived assets and goodwill, which affects depreciation and impairment of long-lived assets, impairment of goodwill and apportionment of goodwill related to divestitures; • potential costs of litigation, which affect operating expenses; • valuation of deferred income taxes, which affects income tax expense (benefit); and • stock-based compensation, which affects gross margin and operating expenses. The Company bases its estimates and assumptions on historical experience and on various other factors that it believes to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities that are not readily apparent from other sources. The actual results experienced by the Company may differ materially and adversely from management’s estimates. To the extent there are material differences between the estimates and actual results, future results of operations will be affected.
Concentrations of Credit Risk and Significant Customers	Concentrations of Credit Risk and Significant Customers The Company's cash, cash equivalents, short-term investments and accounts receivable are potentially subject to concentration of credit risk. Cash and cash equivalents may be redeemable upon demand and are maintained with several financial institutions that management believes are of high credit quality and therefore bear minimal credit risk. The Company's accounts receivables are derived from revenue earned from customers located around the world. The Company mitigates collection risks from its customers by performing regular credit evaluations of customers' financial condition and payment history and requiring collateral, such as letters of credit, corporate guarantee or prepayment, in certain circumstances. The Company sells its products primarily through direct sales force and distributors. Based on direct shipments, 3 customers individually each accounted for at least 10% of total net revenues during the three months ended December 31, 2015 and 2014 and 2 customers individually each accounted for at least 10% of total net revenues during the nine months ended December 31, 2015 and 2014. The Company expects that its largest customers collectively will continue to account for a substantial portion of its net revenue for the foreseeable future.
New Accounting Pronouncements	New Accounting Pronouncements In August 2014, the Financial Accounting Standards Board ("FASB") issued Accounting Standard Update ("ASU") No. 2014-15, "Presentation of Financial Statements - Going Concern, Disclosure of Uncertainties about an Entity’s Ability to Continue as a Going Concern", which requires an entity's management to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the entity’s ability to continue as a going concern within one year after the date that the financial statements are issued or within one year after the date that the financial statements are available to be issued, when applicable. The standard is effective for annual reporting periods beginning after December 15, 2016, including interim periods within that reporting period. The Company is currently evaluating this new standard, and after adoption, it will incorporate this guidance in its assessment of going concern. In May 2014, the FASB issued ASU No. 2014-09, "Revenue from Contracts with Customers", which will supersede most of the existing revenue recognition guidance under U.S. GAAP. This ASU requires an entity to recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services. This standard is effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period. Early adoption is not permitted but adoption on the original effective date is permitted. The ASU allows for either full retrospective or modified retrospective adoption. The Company is currently evaluating the potential effect of this ASU on its financial statements and related disclosures. In November 2015, the FASB issued ASU No. 2015-17, "Income Taxes (Topic 740) - Balance Sheet Classification of Deferred Taxes" to simplify the presentation of deferred taxes in the statement of financial position. The new guidance requires that deferred tax assets and liabilities be classified as non-current in a classified balance sheet. This ASU is effective for fiscal years beginning after December 15, 2016, and for interim periods within those fiscal years. Earlier adoption is permitted as of the beginning of an interim or annual reporting period, and may be applied either prospectively, for all deferred tax assets and liabilities, or retrospectively. The Company is currently evaluating the potential effect of this ASU on its financial position.
Warrant, Intellectual Property Indemnities, Guarantees and Indemnities	Warranty The Company's products typically carry a one-year warranty. The Company establishes reserves for estimated product warranty costs at the time revenue is recognized. Although the Company engages in extensive product quality programs and processes, its warranty obligation is affected by product failure rates, use of materials, and service delivery costs incurred in correcting any product failure. Historically, the Company’s warranty returns have not been material. Intellectual Property Indemnities The Company indemnifies certain customers and contract manufacturers against liability arising from third-party claims of IP rights infringement related to its products. These indemnities appear in development and supply agreements with customers as well as manufacturing service agreements with contract manufacturers and generally survive the expiration of the contract. Given that the amount of any potential liabilities related to such indemnities cannot be determined until an infringement claim has been made, the Company is unable to determine the maximum amount of losses that could be incurred related to such indemnifications. Guarantees and Indemnities In the normal course of business, the Company is occasionally required to provide other guarantees and indemnities for which it may be required to make future payments under specific circumstances. The amount of any potential liabilities related to such obligations cannot be accurately determined until a formal claim is filed. The Company maintains general and product liability insurance which may provide a source of recovery in the event of an indemnification claim.

v3.3.1.900

Certain Financial Statement Information (Tables)	9 Months Ended
	Dec. 31, 2015
Certain Financial Statement Information [Abstract]
Schedule of Accounts receivable	Accounts receivable, net:     December 31, 2015   March 31, 2015     (In thousands) Accounts receivable   $ 12,732   $ 12,709 Less: allowance for bad debts   (280 )   (302 )     $ 12,452   $ 12,407
Schedule of Inventories	Inventories:     December 31, 2015   March 31, 2015     (In thousands) Finished goods   $ 10,405   $ 15,310 Work in process   6,508   5,377 Raw materials   2,779   2,827     $ 19,692   $ 23,514
Schedule of Other current assets	Other current assets:     December 31, 2015   March 31, 2015     (In thousands) Prepaid expenses   $ 12,284   $ 14,847 Executive deferred compensation assets   985   1,004 Other   1,309   989     $ 14,578   $ 16,840
Schedule of Property and equipment	Property and equipment:     Useful Life   December 31, 2015   March 31, 2015     (In years)   (In thousands) Machinery and equipment   3-5   $ 38,244   $ 37,286 Leasehold improvements   1-5   7,528   9,909 Computers, office furniture and equipment   3-5   34,444   32,902         80,216   80,097 Less: accumulated depreciation       (66,868 )   (63,348 )         $ 13,348   $ 16,749
Schedule of Other accrued liabilities	Other accrued liabilities:     December 31, 2015   March 31, 2015     (In thousands) Employee related liabilities   $ 1,377   $ 1,454 Executive deferred compensation   1,017   1,025 Accrued bonus   1,768   39 Income taxes   330   1,311 Other   4,491   3,815     $ 8,983   $ 7,644
Schedule of Cash, cash equivalents and available-for-sale investments by type of instruments	Short-term investments: The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument (in thousands):   December 31, 2015   March 31, 2015   Amortized Cost   Gross Unrealized   Estimated Fair Value   Amortized Cost   Gross Unrealized   Estimated Fair Value   Gains   Losses   Gains   Losses   Cash $ 16,299   $ —   $ —   $ 16,299   $ 33,936   $ —   $ —   $ 33,936 Cash equivalents 2,471   —   —   2,471   2,559   —   —   2,559 U.S. Treasury securities and agency bonds 17,855   —   (54 )   17,801   1,230   —   —   1,230 Corporate bonds 25,957   18   (63 )   25,912   10,772   28   (6 )   10,794 Asset-backed and mortgage-backed securities 11,948   1   (50 )   11,899   —   15   —   15 Municipal bonds 2,071   —   (10 )   2,061   —   —   —   — Mutual funds —   —   —   —   24,895   1,955   (59 )   26,791 Preferred stock —   —   —   —   11   22   —   33   $ 76,601   $ 19   $ (177 )   $ 76,443   $ 73,403   $ 2,020   $ (65 )   $ 75,358 Reported as:                               Cash and cash equivalents             $ 18,770               $ 36,495 Short-term investments available-for-sale             57,673               38,863               $ 76,443               $ 75,358
Schedule of Cash, cash equivalents and available-for-sale investments by type of instruments measured at fair value on recurring basis	The following is a summary of cash, cash equivalents and available-for-sale investments by type of instrument measured at fair value on a recurring basis (in thousands):     December 31, 2015   March 31, 2015     Level 1   Level 2   Level 3   Total   Level 1   Level 2   Level 3   Total Cash   $ 16,299   $ —   $ —   $ 16,299   $ 33,936   $ —   $ —   $ 33,936 Cash equivalents   2,071   400   —   2,471   2,559   —   —   2,559 U.S. Treasury securities and agency bonds   17,801   —   —   17,801   1,230   —   —   1,230 Corporate bonds   —   25,912   —   25,912   —   10,794   —   10,794 Asset-backed and mortgage-backed securities   —   11,899   —   11,899   —   15   —   15 Municipal bonds   —   2,061   —   2,061   —   —   —   — Mutual funds   —   —   —   —   26,791   —   —   26,791 Preferred stock   —   —   —   —   —   33   —   33     $ 36,171   $ 40,272   $ —   $ 76,443   $ 64,516   $ 10,842   $ —   $ 75,358
Schedule of Cost and estimated fair values of available-for-sale securities with stated maturities by contractual maturity	The following is a summary of the cost and estimated fair values of available-for-sale securities with stated maturities, which include U.S. Treasury securities and agency bonds, corporate bonds, asset-backed and mortgage-backed securities and municipal bonds, by contractual maturity (in thousands):     December 31, 2015     Cost   Estimated Fair Value Less than 1 year   $ 15,500   $ 15,485 Mature in 1 – 2 years   31,021   30,908 Mature in 3 – 5 years   11,310   11,280 Mature after 5 years   —   —     $ 57,831   $ 57,673
Schedule of Gross unrealized losses	The following is a summary of gross unrealized losses (in thousands): As of December 31, 2015   Less Than 12 Months of Unrealized Losses   12 Months or More of Unrealized Losses   Total     Estimated Fair Value   Gross Unrealized Losses   Estimated Fair Value   Gross Unrealized Losses   Estimated Fair Value   Gross Unrealized Losses U.S. Treasury securities and agency bonds   $ 17,260   $ (54 )   $ —   $ —   $ 17,260   $ (54 ) Corporate bonds   18,243   (63 )   —   —   18,243   (63 ) Asset-backed and mortgage-backed securities   10,793   (50 )   —   —   10,793   (50 ) Municipal bonds   1,898   (10 )   —   —   1,898   (10 )     $ 48,194   $ (177 )   $ —   $ —   $ 48,194   $ (177 ) As of March 31, 2015   Less Than 12 Months of Unrealized Losses   12 Months or More of Unrealized Losses   Total     Estimated Fair Value   Gross Unrealized Losses   Estimated Fair Value   Gross Unrealized Losses   Estimated Fair Value   Gross Unrealized Losses Corporate bonds   $ 878   $ (6 )   $ —   $ —   $ 878   $ (6 ) Mutual funds   14,592   (17 )   475   (42 )   15,067   (59 )     $ 15,470   $ (23 )   $ 475   $ (42 )   $ 15,945   $ (65 )
Schedule of Interest income, net	Realized gain on short-term investments and interest income, net (in thousands):     Three Months Ended December 31,   Nine Months Ended December 31,     2015   2014   2015   2014 Net realized gain (loss) on short-term investments   $ (2 )   $ 123   $ 1,557   $ 123 Interest income, net   150   362   467   1,091     $ 148   $ 485   $ 2,024   $ 1,214
Schedule of potentially dilutive common shares excluded from EPS computation	The following potentially dilutive common shares are excluded from the computation of net loss per share (in thousands):     December 31, 2015   December 31, 2014 Outstanding stock options   1,650   1,882 Outstanding RSUs   4,752   4,642 ESPP shares   365   350     6,767   6,874

v3.3.1.900

Restructuring Charges (Tables)	9 Months Ended
	Dec. 31, 2015
Restructuring and Related Activities [Abstract]
Schedule of restructuring activity	The following table sets forth a summary of restructuring activities related to the Company's restructuring plan described above (in thousands):     Workforce Reduction   Operating Lease Commitments   Other   Total Liability, March 31, 2015   $ 449   $ 113   $ 15   $ 577 Restructuring charges   80   —   2   82 Cash payments   (286 )   (61 )   (9 )   (356 ) Non-cash items   (22 )   12   (8 )   (18 ) Liability, December 31, 2015   $ 221   $ 64   $ —   $ 285

v3.3.1.900

Veloce (Tables)	9 Months Ended
	Dec. 31, 2015
Business Combinations [Abstract]
Schedule of cash payments and stock issuance activities	The following table summarizes the cash payment and stock issuance activities during the three and nine months ended December 31, 2015 and 2014 as part of the above arrangement (in thousands):   Three Months Ended December 31,   Nine Months Ended December 31,   2015   2014   2015   2014 Cash payments $ 9   $ 1,482   $ 99   $ 8,981 Value of common stock issued 1   257   2,869   872 Total payments $ 10   $ 1,739   $ 2,968   $ 9,853 Shares of common stock issued —   39   517   116

v3.3.1.900

Stockholders' Equity (Tables)	9 Months Ended
	Dec. 31, 2015
Equity [Abstract]
Schedule of Option Activity Under Stock Incentive Plans	A summary of the Company's stock option activities and related information during the nine months ended December 31, 2015 is as follows:     Number of Shares (thousands)   Weighted Average Exercise Price Per Share   Weighted Average Remaining Contractual Term (years)   Aggregate Intrinsic Value (millions)   Outstanding at the beginning of the year   1,794   $ 9.15           Granted   —   —         Exercised   (25 )   $ 5.23     — (1 ) Cancelled   (119 )   $ 10.91           Outstanding, vested and exercisable at the end of the period   1,650   $ 9.09   1.2   $ 0.1 (2 ) (1) The aggregate pre-tax intrinsic value is calculated as the difference between the market value on the date of exercise and the exercise price of the shares. (2) The aggregate pre-tax intrinsic value is calculated as the difference between the market value as of December 31, 2015 and the exercise price of the shares. The closing price of the Company’s common stock was $6.37 per share on December 31, 2015.
Schedule of Restricted Stock Unit Activity	RSU activities during the nine months ended December 31, 2015 is set forth below (in thousands):   Number of Shares Outstanding at the beginning of the year 4,328 Awarded 3,406 Vested (2,202 ) Cancelled (780 ) Outstanding at the end of the period 4,752

v3.3.1.900

Stock-Based Compensation (Tables)	9 Months Ended
	Dec. 31, 2015
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Assumptions Used	The Company did not grant employee stock purchase rights during the three months ended December 31, 2015. The fair values of the employee stock purchase rights granted during the nine months ended December 31, 2015 and 2014 are estimated as of the grant date using the Black-Scholes option-pricing model with the following assumptions:   Nine Months Ended December 31,   2015   2014 Expected life (years) 0.5   0.5 Risk-free interest rate 0.1 %   0.1 % Volatility 57 %   57 % Weighted average fair value $ 1.80   $ 2.57
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units	The following tables summarize the allocation of the stock-based compensation expense (in thousands): Stock-based compensation expense by type of grant: Three Months Ended December 31,   Nine Months Ended December 31,   2015   2014   2015   2014 Stock options and stock purchase rights $ 352   $ 454   $ 848   $ 1,160 RSUs 5,800   4,428   17,347   13,148   6,152   4,882   18,195   14,308 Stock-based compensation capitalized to inventory (11 )   (25 )   (28 )   (5 ) Total $ 6,141   $ 4,857   $ 18,167   $ 14,303
Summary of Stock-Based Compensation Expense	Stock-based compensation expense by cost centers: Three Months Ended December 31,   Nine Months Ended December 31,   2015   2014   2015   2014 Cost of revenues $ 151   $ 97   $ 377   $ 226 Research and development 4,500   2,992   12,515   9,039 Selling, general and administrative 1,501   1,793   5,303   5,043   6,152   4,882   18,195   14,308 Stock-based compensation capitalized to inventory (11 )   (25 )   (28 )   (5 ) Total $ 6,141   $ 4,857   $ 18,167   $ 14,303

v3.3.1.900

Commitments and Contingencies (Tables)	9 Months Ended
	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Schedule of Contractual Obligation by Fiscal Year Maturity	The following table summarizes the Company's contractual operating leases and other purchase commitments as of December 31, 2015 (in thousands): Fiscal Years Ending March 31, Operating Leases   Purchase Commitments *   Total 2016 (remainder of year) $ 718   $ 22,277   $ 22,995 2017 2,350   10,814    13,164 2018 824   5,225    6,049 2019 472   378    850 Total minimum payments $ 4,364   $ 38,694    $ 43,058 * Includes open purchase orders with terms that generally allow us the option to cancel or reschedule the order, subject to various restrictions and limitations. Also includes the licensing fees relating to the Company's R&D efforts, including IP, technology, product design, test and verification tools, of $15.4 million.

v3.3.1.900

Certain Financial Statement Information - Accounts Receivable (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Schedule of Accounts receivable
Accounts receivable	$ 12,732	$ 12,709
Less: allowance for bad debts	(280)	(302)
Accounts receivable, net	$ 12,452	$ 12,407	[1]
[1] The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

v3.3.1.900

Certain Financial Statement Information - Inventories (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Schedule of Inventories
Finished goods	$ 10,405	$ 15,310
Work in process	6,508	5,377
Raw materials	2,779	2,827
Inventories, total	$ 19,692	$ 23,514	[1]
[1] The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

v3.3.1.900

Certain Financial Statement Information - Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Schedule of Other current assets
Prepaid expenses	$ 12,284	$ 14,847
Executive deferred compensation assets	985	1,004
Other	1,309	989
Other current assets, total	$ 14,578	$ 16,840	[1]
[1] The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

v3.3.1.900

Certain Financial Statement Information - Property and Equipment (Details) - USD ($) $ in Thousands	9 Months Ended
	Dec. 31, 2015	Mar. 31, 2015
Schedule of Property and equipment
Machinery and equipment	$ 38,244	$ 37,286
Leasehold improvements	7,528	9,909
Computers, office furniture and equipment	34,444	32,902
Property and equipment, gross	80,216	80,097
Less: accumulated depreciation	(66,868)	(63,348)
Property and equipment, net	$ 13,348	$ 16,749	[1]
Machinery and Equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Machinery and Equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Leasehold Improvements | Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	1 year
Leasehold Improvements | Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
Computers, Office Furniture and Equipment | Minimum
Property, Plant and Equipment [Line Items]
Useful life (in years)	3 years
Computers, Office Furniture and Equipment | Maximum
Property, Plant and Equipment [Line Items]
Useful life (in years)	5 years
[1] The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

v3.3.1.900

Certain Financial Statement Information - Other Accrued Liabiliteis (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Schedule of other accrued liabilities
Employee related liabilities	$ 1,377	$ 1,454
Executive deferred compensation	1,017	1,025
Accrued bonus	1,768	39
Income taxes	330	1,311
Other	4,491	3,815
Total other accrued liabilities	$ 8,983	$ 7,644	[1]
[1] The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements.

v3.3.1.900

Certain Financial Statement Information - Short-Term Investments (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015		Dec. 31, 2014	[2]	Mar. 31, 2014	[2]
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	$ 76,601	$ 73,403
Available-for-sale Securities, Gross Unrealized Gains	19	2,020
Available-for-sale Securities, Gross Unrealized Losses	(177)	(65)
Available-for-sale Securities, Estimated Fair Value	76,443	75,358
Cash and cash equivalents	18,770	36,495	[1]	$ 50,080		$ 71,539
Short-term investments available-for-sale	57,673	38,863	[1]
Cash, Cash equivalents and Short-term investments, Estimated Fair Value	76,443	75,358
Cash
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Cash and Cash equivalents, Estimated Fair Value	16,299	33,936
Cash equivalents
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Cash and Cash equivalents, Estimated Fair Value	2,471	2,559
U.S Treasury securities and agency bonds
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	17,855	1,230
Available-for-sale Securities, Gross Unrealized Gains	0	0
Available-for-sale Securities, Gross Unrealized Losses	(54)	0
Available-for-sale Securities, Estimated Fair Value	17,801	1,230
Corporate bonds
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	25,957	10,772
Available-for-sale Securities, Gross Unrealized Gains	18	28
Available-for-sale Securities, Gross Unrealized Losses	(63)	(6)
Available-for-sale Securities, Estimated Fair Value	25,912	10,794
Asset-backed and mortgage-backed securities
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	11,948	0
Available-for-sale Securities, Gross Unrealized Gains	1	15
Available-for-sale Securities, Gross Unrealized Losses	(50)	0
Available-for-sale Securities, Estimated Fair Value	11,899	15
Municipal bonds
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	2,071	0
Available-for-sale Securities, Gross Unrealized Gains	0	0
Available-for-sale Securities, Gross Unrealized Losses	(10)	0
Available-for-sale Securities, Estimated Fair Value	2,061	0
Mutual Funds
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	0	24,895
Available-for-sale Securities, Gross Unrealized Gains	0	1,955
Available-for-sale Securities, Gross Unrealized Losses	0	(59)
Available-for-sale Securities, Estimated Fair Value	0	26,791
Preferred stock
Schedule of cash, cash equivalents and available-for-sale investments by type of instruments
Available-for-sale Securities, Amortized Cost	0	11
Available-for-sale Securities, Gross Unrealized Gains	0	22
Available-for-sale Securities, Gross Unrealized Losses	0	0
Available-for-sale Securities, Estimated Fair Value	$ 0	$ 33
[1] The Condensed Consolidated Balance Sheet as of March 31, 2015 has been derived from the audited Consolidated Financial Statements at that date but does not include all disclosures required by generally accepted accounting principles for complete financial statements. [2] The Statement of Cash Flows for the nine months ended December 31, 2014 reflects immaterial revisions to correct $0.3 million of outstanding payables related to purchases of property and equipment previously included in net cash used for investing activities to net cash used for operating activities and $0.1 million of net realized gains on short-term investments previously classified as net cash used for operating activities to net cash provided by investing activities. As a result, net cash used for operating activities increased by $0.4 million and net cash used for investing activities decreased by the corresponding amount.

v3.3.1.900

Certain Financial Statement Information - Short Term Investments Fair Value (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	$ 76,443	$ 75,358
Cash
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	16,299	33,936
Cash equivalents
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	2,471	2,559
U.S Treasury securities and agency bonds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	17,801	1,230
Corporate bonds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	25,912	10,794
Asset-backed and mortgage-backed securities
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	11,899	15
Municipal bonds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	2,061	0
Mutual Funds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	26,791
Preferred stock
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	33
Recurring
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash, cash equivalents and available-for-sale investments	76,443	75,358
Recurring | Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash, cash equivalents and available-for-sale investments	36,171	64,516
Recurring | Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash, cash equivalents and available-for-sale investments	40,272	10,842
Recurring | Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash, cash equivalents and available-for-sale investments	0	0
Recurring | Cash
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	16,299	33,936
Recurring | Cash | Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	16,299	33,936
Recurring | Cash | Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	0	0
Recurring | Cash | Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	0	0
Recurring | Cash equivalents
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	2,471	2,559
Recurring | Cash equivalents | Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	2,071	2,559
Recurring | Cash equivalents | Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	400	0
Recurring | Cash equivalents | Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Cash and cash equivalents	0	0
Recurring | U.S Treasury securities and agency bonds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	17,801	1,230
Recurring | U.S Treasury securities and agency bonds | Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	17,801	1,230
Recurring | U.S Treasury securities and agency bonds | Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring | U.S Treasury securities and agency bonds | Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring | Corporate bonds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	25,912	10,794
Recurring | Corporate bonds | Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring | Corporate bonds | Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	25,912	10,794
Recurring | Corporate bonds | Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring | Asset-backed and mortgage-backed securities
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	11,899	15
Recurring | Asset-backed and mortgage-backed securities | Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring | Asset-backed and mortgage-backed securities | Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	11,899	15
Recurring | Asset-backed and mortgage-backed securities | Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring | Municipal bonds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	2,061	0
Recurring | Municipal bonds | Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring | Municipal bonds | Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	2,061	0
Recurring | Municipal bonds | Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring | Mutual Funds
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	26,791
Recurring | Mutual Funds | Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	26,791
Recurring | Mutual Funds | Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring | Mutual Funds | Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring | Preferred stock
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	33
Recurring | Preferred stock | Level 1
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	0
Recurring | Preferred stock | Level 2
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	0	33
Recurring | Preferred stock | Level 3
Schedule of Cash, Cash Equivalents and Available-For-Sale Investments by Type of Instruments Measured at Fair Value on Recurring Basis
Available-for-sale securities	$ 0	$ 0

v3.3.1.900

Certain Financial Statement Information - Short-Term Investments Schedule of Maturities (Details) $ in Thousands	Dec. 31, 2015 USD ($)
Schedule of cost and estimated fair values of available-for-sale securities with stated maturities by contractual maturity
Less than 1 year, Cost	$ 15,500
Mature in 1 - 2 years, Cost	31,021
Mature in 3 - 5 years, Cost	11,310
Mature after 5 years, Cost	0
Cost, Total	57,831
Less than 1 year, Fair Value	15,485
Mature in 1 - 2 years, Fair Value	30,908
Mature in 3 - 5 years, Fair Value	11,280
Mature after 5 years, Fair Value	0
Fair Value, Total	$ 57,673

v3.3.1.900

Certain Financial Statement Information - Short-Term Investments Gross Unrealized Losses (Details) - USD ($) $ in Thousands	Dec. 31, 2015	Mar. 31, 2015
Schedule of Gross Unrealized Losses
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	$ 48,194	$ 15,470
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses	(177)	(23)
12 Months or More of Unrealized Losses, Estimated Fair Value	0	475
12 Months or More of Unrealized Losses, Gross Unrealized Losses	0	(42)
Total, Estimated Fair Value	48,194	15,945
Total Gross Unrealized Losses	(177)	(65)
U.S. Treasury securities and agency bonds
Schedule of Gross Unrealized Losses
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	17,260
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses	(54)
12 Months or More of Unrealized Losses, Estimated Fair Value	0
12 Months or More of Unrealized Losses, Gross Unrealized Losses	0
Total, Estimated Fair Value	17,260
Total Gross Unrealized Losses	(54)
Corporate bonds
Schedule of Gross Unrealized Losses
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	18,243	878
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses	(63)	(6)
12 Months or More of Unrealized Losses, Estimated Fair Value	0	0
12 Months or More of Unrealized Losses, Gross Unrealized Losses	0	0
Total, Estimated Fair Value	18,243	878
Total Gross Unrealized Losses	(63)	(6)
Asset-backed and mortgage-backed securities
Schedule of Gross Unrealized Losses
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	10,793
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses	(50)
12 Months or More of Unrealized Losses, Estimated Fair Value	0
12 Months or More of Unrealized Losses, Gross Unrealized Losses	0
Total, Estimated Fair Value	10,793
Total Gross Unrealized Losses	(50)
Municipal bonds
Schedule of Gross Unrealized Losses
Less Than 12 Months of Unrealized Losses, Estimated Fair Value	1,898
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses	(10)
12 Months or More of Unrealized Losses, Estimated Fair Value	0
12 Months or More of Unrealized Losses, Gross Unrealized Losses	0
Total, Estimated Fair Value	1,898
Total Gross Unrealized Losses	$ (10)
Mutual Funds
Schedule of Gross Unrealized Losses
Less Than 12 Months of Unrealized Losses, Estimated Fair Value		14,592
Less than 12 Months of Unrealized Losses, Gross Unrealized Losses		(17)
12 Months or More of Unrealized Losses, Estimated Fair Value		475
12 Months or More of Unrealized Losses, Gross Unrealized Losses		(42)
Total, Estimated Fair Value		15,067
Total Gross Unrealized Losses		$ (59)

v3.3.1.900

Certain Financial Statement Information - Realized Gain on Short-Term Investments and Interest Income, Net (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Schedule of Interest Income, Net
Net realized gain (loss) on short-term investments	$ (2)	$ 123	$ 1,557	$ 123
Interest income, net	150	362	467	1,091
Realized gain on short-term investments and interest income, net	$ 148	$ 485	$ 2,024	$ 1,214

v3.3.1.900

Certain Financial Statement Information - Potentially Dilutive Common Shares (Details) - shares shares in Thousands	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Certain Financial Statement Information [Line Items]
Dilutive securities excluded from the net loss per share computation	6,767	6,874
Outstanding stock options
Certain Financial Statement Information [Line Items]
Dilutive securities excluded from the net loss per share computation	1,650	1,882
Outstanding RSUs
Certain Financial Statement Information [Line Items]
Dilutive securities excluded from the net loss per share computation	4,752	4,642
ESPP shares
Certain Financial Statement Information [Line Items]
Dilutive securities excluded from the net loss per share computation	365	350

v3.3.1.900

Restructuring Charges - Additional Information (Details) $ in Thousands	1 Months Ended	3 Months Ended		9 Months Ended		12 Months Ended
	Jan. 31, 2015 employee	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Dec. 31, 2015 USD ($)
Restructuring Cost and Reserve [Line Items]
Restructuring charges		$ (29)	$ 221	$ 82	$ 1,322
Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Number of positions eliminated | employee	40
Number of positions expected to be eliminated (percent)	7.00%
Restructuring charges						$ 4,200

v3.3.1.900

Restructuring Charges - Restructuring Activities (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Restructuring Reserve [Roll Forward]
Liability, beginning balance			$ 577
Restructuring charges	$ (29)	$ 221	82	$ 1,322
Cash payments			(356)
Non-cash items			(18)
Liability, ending balance	285		285
Workforce Reduction [Member]
Restructuring Reserve [Roll Forward]
Liability, beginning balance			449
Restructuring charges			80
Cash payments			(286)
Non-cash items			(22)
Liability, ending balance	221		221
Operating Lease Commitments [Member]
Restructuring Reserve [Roll Forward]
Liability, beginning balance			113
Restructuring charges			0
Cash payments			(61)
Non-cash items			12
Liability, ending balance	64		64
Other [Member]
Restructuring Reserve [Roll Forward]
Liability, beginning balance			15
Restructuring charges			2
Cash payments			(9)
Non-cash items			(8)
Liability, ending balance	$ 0		$ 0

v3.3.1.900

Veloce - Additional Information (Details) - Veloce Technologies Inc - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended		43 Months Ended
	Jun. 20, 2012	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015
Business Acquisition [Line Items]
Total purchase consideration	$ 178,500	$ 10	$ 1,739	$ 2,968	$ 9,853	$ 171,900
Cash payments		$ 9	$ 1,482	$ 99	$ 8,981	$ 89,400
Stock issued (in shares)		0	39	517	116	11,200
Cash and stock to be paid in next period		$ 2,200		$ 2,200		$ 2,200
Total equity value transferred						82,500
Consideration payable in cash or equity		$ 6,600		$ 6,600		$ 6,600

v3.3.1.900

Veloce - Cash Payments and Stock Issuances (Details) - Veloce Technologies Inc - USD ($) shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended		43 Months Ended
	Jun. 20, 2012	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015
Business Acquisition [Line Items]
Cash payments		$ 9	$ 1,482	$ 99	$ 8,981	$ 89,400
Value of common stock issued		1	257	2,869	872
Total payments	$ 178,500	$ 10	$ 1,739	$ 2,968	$ 9,853	$ 171,900
Shares of common stock issued (in shares)		0	39	517	116	11,200

v3.3.1.900

Stockholders' Equity - Stock Options (Details) $ / shares in Units, shares in Thousands, $ in Millions	9 Months Ended
	Dec. 31, 2015 USD ($) Approved_Plan $ / shares shares
Equity [Abstract]
Number of stockholder-approved plans | Approved_Plan	2
Number of plans unapproved by stockholders | Approved_Plan	1
Schedule of Option Activity Under Stock Incentive Plans
Number of Shares, Outstanding at the beginning of the year (in shares) | shares	1,794
Number of Shares, Granted (in shares) | shares	0
Number of Shares, Exercised (in shares) | shares	(25)
Number of Shares, Forfeited (in shares) | shares	(119)
Number of Shares, Outstanding at the end of the period (in shares) | shares	1,650
Number of Shares vested and exercisable at end of period (in shares) | shares	1,650
Schedule of Weighted Average Exercise Price Per Share Under Stock Incentive Plans
Weighted Average Exercise Price Per Share, Outstanding at the beginning of the year (USD per share)	$ 9.15
Weighted Average Exercise Price Per Share, Granted (USD per share)	0.00
Weighted Average Exercise Price Per Share, Exercised (USD per share)	5.23
Weighted Average Exercise Price Per Share, Forfeited (USD per share)	10.91
Weighted Average Exercise Price Per Share, Outstanding at the end of the period (USD per share)	9.09
Weighted Average Exercise Price Per Share, vested and exercisable at the end of the period (USD per share)	$ 9.09
Weighted average remaining contractual term for options outstanding at end of period (in years)	1 year 2 months 24 days
Weighted Average Remaining Contractual Life, vested and exercisable at end of period (in years)	1 year 2 months 24 days
Aggregate pretax intrinsic value of options exercised | $	$ 0.0	[1]
Aggregate intrinsic value of options outstanding at end of period | $	0.1	[2]
Aggregate intrinsic value of options, vested and exercisable at end of period | $	$ 0.0	[2]
Common stock, closing price per share (USD per share)	$ 6.37
[1] The aggregate pre-tax intrinsic value is calculated as the difference between the market value on the date of exercise and the exercise price of the shares. [2] The aggregate pre-tax intrinsic value is calculated as the difference between the market value as of December 31, 2015 and the exercise price of the shares. The closing price of the Company’s common stock was $6.37 per share on December 31, 2015.

v3.3.1.900

Stockholders' Equity - Restricted Stock Units (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Millions	9 Months Ended	31 Months Ended
	Dec. 31, 2015	Nov. 30, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Common stock, closing price per share (USD per share)	$ 6.37
Outstanding RSUs
Share-based Compensation Arrangement by Share-based Payment Award, Equity Instruments Other than Options, Nonvested, Number of Shares [Roll Forward]
Number of Shares, Beginning balance (in shares)	4,328
Number of Shares, Awarded (in shares)	3,406
Number of Shares, Vested (in shares)	(2,202)
Number of Shares, Cancelled (in shares)	(780)
Number of Shares, Ending balance (in shares)	4,752
Weighted average remaining contractual term for the restricted stock units outstanding (in years)	1 year 2 months 10 days
Aggregate pre-tax intrinsic value of restricted stock units outstanding which includes performance based awards which are subject to milestone attainments	$ 30.3
Aggregate pretax intrinsic value	13.9
Performance-Based MSU
Class of Stock [Line Items]
Grants in period, fair value		$ 5.5
Value of shares expired unvested in period	$ 2.6
Performance-Based MSU | First Vesting period
Class of Stock [Line Items]
Award performance period	2 years
Performance-Based MSU | First Vesting period | Minimum
Class of Stock [Line Items]
Vesting percentage	0.00%
Performance-Based MSU | First Vesting period | Maximum
Class of Stock [Line Items]
Vesting percentage	150.00%
Performance-Based MSU | Second Vesting Period
Class of Stock [Line Items]
Award performance period	3 years
Performance-Based MSU | Second Vesting Period | Minimum
Class of Stock [Line Items]
Vesting percentage	0.00%
Performance-Based MSU | Second Vesting Period | Maximum
Class of Stock [Line Items]
Vesting percentage	175.00%
1992 Equity Incentive Plan | Outstanding RSUs | Maximum
Class of Stock [Line Items]
Vesting period, in years	4 years
2011 Equity Incentive Plan | Outstanding RSUs | Maximum
Class of Stock [Line Items]
Vesting period, in years	4 years
Compensation Programs | Minimum
Class of Stock [Line Items]
Award pay out percentage	0.00%
Compensation Programs | Maximum
Class of Stock [Line Items]
Award pay out percentage	150.00%

v3.3.1.900

Stockholders' Equity - Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan - 2012 Employee Stock Purchase Plan - USD ($) $ / shares in Units, shares in Millions, $ in Millions	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Class of Stock [Line Items]
Common stock reserved for issuance (in shares)	3.8
Percentage of purchase price of common stock equal to fair market value	85.00%
Shares available for future issuance (in shares)	1.6
Average purchase price of shares purchased (in dollars per share)	$ 4.46	$ 7.09
Number of shares purchased (in shares)	0.2	0.2
Intrinsic value of shares purchased	$ 0.4	$ 0.3

v3.3.1.900

Stock-Based Compensation - Fair Value Assumptions (Details) - Employee Stock Purchase Plan - $ / shares	9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (years)	6 months	6 months
Risk-free interest rate	0.10%	0.10%
Volatility	57.00%	57.00%
Weighted average fair value (in dollars per share)	$ 1.80	$ 2.57

v3.3.1.900

Stock-Based Compensation - Stock Based Compensation Expense (Details) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units
Stock-based compensation expense	$ 6,152	$ 4,882	$ 18,195	$ 14,308
Stock-based compensation capitalized to inventory	(11)	(25)	(28)	(5)
Total	6,141	4,857	18,167	14,303
Cost of Revenues
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units
Stock-based compensation expense	151	97	377	226
Research and Development Expense
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units
Stock-based compensation expense	4,500	2,992	12,515	9,039
Selling, General and Administrative
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units
Stock-based compensation expense	1,501	1,793	5,303	5,043
Outstanding stock options
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units
Stock-based compensation expense	352	454	848	1,160
Outstanding RSUs
Summary of Stock-Based Compensation Expense of Stock Options and Restricted Stock Units
Stock-based compensation expense	$ 5,800	$ 4,428	$ 17,347	$ 13,148

v3.3.1.900

Stock-Based Compensation - Additional Information (Details) - USD ($) $ / shares in Units, $ in Millions	3 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2015	Dec. 31, 2014
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Weighted average grant-date fair value per share of the restricted stock units awarded (in dollars per share)	$ 6.87	$ 5.82	$ 5.01	$ 8.20
Unearned stock-based compensation	$ 33.4		$ 33.4
Weighted-average period over which the unearned stock-based compensation is expected to be recognized, years			1 year 2 months

v3.3.1.900

Commitments and Contingencies - Commitments (Details) $ in Thousands	9 Months Ended
	Dec. 31, 2015 USD ($)
Operating Leases
2016 (remainder of year)	$ 718
2017	2,350
2018	824
2019	472
Total minimum payments	4,364
Purchase Commitments
2016 (remainder of year)	22,277	[1]
2017	10,814	[1]
2018	5,225	[1]
2019	378	[1]
Total minimum payments	38,694	[1]
Total
2016 (remainder of year)	22,995
2017	13,164
2018	6,049
2019	850
Total minimum payments	43,058
Licensing Costs Due	$ 15,400
Length of warranty (in years)	1 year
[1] Includes open purchase orders with terms that generally allow us the option to cancel or reschedule the order, subject to various restrictions and limitations. Also includes the licensing fees relating to the Company's R&D efforts, including IP, technology, product design, test and verification tools, of $15.4 million.

v3.3.1.900

Commitments and Contingencies - Contingencies (Details) - Company	1 Months Ended	9 Months Ended
	Jan. 31, 2012	Dec. 31, 2015
Commitments and Contingencies Disclosure [Abstract]
Companies named as Potentially Responsible Parties (more than)		100
Percent of contribution to the total waste	0.50%